Health Economics›Breast cancer›Adjuvant therapy premenopausal women and men

Adjuvant therapy premenopausal women and men

Breast cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Leuprolide monotherapy Variant #01	ER	R 253 833	90d	—	—	~2	~R 507 665 PFS proxy · indirect	2
Goserelin, Letrozole, Ribociclib Variant #01	ER	R 23 809	28d	~22.8 mo	~58.7 mo	~2	~R 47 617 PFS proxy · indirect	3
Anastrozole, Goserelin, Ribociclib Variant #01	ER	R 23 597	28d	~22.8 mo	~58.7 mo	~2	~R 47 194 PFS proxy · indirect	3
Goserelin and Tamoxifen Variant #01	ER	R 8 293	28d	~13.0 mo	~48.0 mo	~2	~R 16 587 PFS proxy · indirect	2
Tamoxifen and OFS Variant not yet assigned - class-based regimen Partial	ER	R 6 928	28d	—	—	65	R 275 936 PFS proxy	3
Goserelin and Letrozole Variant #01	ER	R 2 999	28d	~13.0 mo	~48.0 mo	~2	~R 5 997 PFS proxy · indirect	2
Anastrozole and Goserelin Variant #01	ER	R 2 787	28d	~13.0 mo	~48.0 mo	~2	~R 5 574 PFS proxy · indirect	2
Goserelin monotherapy Variant #01	ER	R 2 628	28d	—	—	~26	~R 68 324 indirect	—
Exemestane and OFS Variant #01 Partial	ER	R 2 421	28d	—	—	~65	~R 157 356 indirect	—
Tamoxifen monotherapy Variant #01	ER	R 273	28d	—	—	12	R 3 279 PFS proxy	3

10 of 10 regimens shown